Sickle Cell Care Reaches an Inflection Point as Gene Therapy Enthusiasm Rises, but Referral Pathways and Uptake Lag Due to Treatment Burden
New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime Exton, PA – March 10, 2026 – Spherix Global Insights today announced the release of its 2026 Patient Chart Dynamix™: Sickle Cell Disease (US) report, an in-depth analysis of 133 real-world patient charts collected from 86 U.S. hematologist/oncologists offering insight into current […]
FDA Approves Deucravacitinib (Sotyktu), First TYK2 Inhibitor for Psoriatic Arthritis
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials. he FDA approveddeucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), the company announced March 7, 2026.¹ The decision makes deucravacitinib the first oral TYK2 inhibitor approved for PsA — and […]
Spherix Global Insights Expands Advisory Capabilities with Launch of a New Market Access Suite of Services
EXTON, PA, March 3, 2026 — Spherix Global Insights today announced the launch of a new suite of services focused on Market Access, expanding the company’s advisory capabilities to provide biopharma manufacturers and other stakeholders with comprehensive, data-driven insights across payer strategy, key account dynamics, organized customer engagement, and patient services optimization. This expansion represents a natural evolution […]
Rheumatologists Sharpen Differentiation Across the SLE Pipeline as Late-Stage Assets Crystallize into More Defined Clinical Roles, According to Spherix Global Insights
Nearly half of US rheumatologists expect Gazyva to meaningfully reshape SLE treatment pathways, while CAR T-cell therapy is viewed as applicable to only a small, refractory subset of patients EXTON, PA, January 20, 2026 – Updated findings from the Q4 2025 Market Dynamix™: SLE, Pipeline Refresh reveal a maturing and increasingly stratified development landscape, as US rheumatologists move from broad enthusiasm toward more selective, indication-driven […]
Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while viewing subcutaneous PD-1s as a practical evolution in care delivery more than a major paradigm shift. EXTON, PA., January 14, 2026 — Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S. oncologists. The research reveals growing use of subcutaneous (SC) PD-1 therapies alongside expectations for an eventual shift toward biosimilars across non-small cell lung cancer […]
Spherix Global Insights Reveals Unmet Need Driving Interest in Emerging Therapies for Thyroid Eye Disease
Physicians highlight early intervention, safety, and access limitations as key unmet needs—Tepezza SC anticipated to reshape the treatment paradigm in 2026 EXTON, PA, November 12, 2025 — New research from Spherix Global Insights finds that while Amgen’s Tepezza (teprotumumab) continues to anchor the treatment landscape for thyroid eye disease (TED), physicians emphasize ongoing unmet needs—particularly […]